2011
DOI: 10.1016/j.jaad.2009.12.062
|View full text |Cite
|
Sign up to set email alerts
|

The value of molecular diagnostics in primary cutaneous B-cell lymphomas in the context of clinical findings, histology, and immunohistochemistry

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
47
0
6

Year Published

2011
2011
2019
2019

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 34 publications
(53 citation statements)
references
References 28 publications
(54 reference statements)
0
47
0
6
Order By: Relevance
“…Although MALT lymphoma is a B-cell lymphoma, it rarely accounts for MTX-LPD [6]. In the present case, we diagnosed MALT lymphoma on the basis of the histopathologic analysis, although immunoglobulin heavy chain gene rearrangement or flow cytometry is necessary to confirm the monoclonality of B cells in orbital LPDs [7]. On the other hand, the [8].…”
Section: Discussionmentioning
confidence: 93%
“…Although MALT lymphoma is a B-cell lymphoma, it rarely accounts for MTX-LPD [6]. In the present case, we diagnosed MALT lymphoma on the basis of the histopathologic analysis, although immunoglobulin heavy chain gene rearrangement or flow cytometry is necessary to confirm the monoclonality of B cells in orbital LPDs [7]. On the other hand, the [8].…”
Section: Discussionmentioning
confidence: 93%
“…74 Clonal immunoglobulin gene rearrangements can be detected in more than 90% of cases. 75,76 PCFCL has an excellent prognosis with more than 95% 5-year survival. 73,77 Small, well-demarcated solitary lesions are treated with surgical excision or radiation therapy with 40-70% of patients having cutaneous relapses.…”
Section: Primary Cutaneous Follicle Center Lymphomamentioning
confidence: 99%
“…81,84,85 but clonality can usually be shown by PCR. 75,76 PCMZL is an indolent disease with a 5-year disease-specific survival of over 95%. 77 Staging procedures with whole body imaging are recommended to rule out cutaneous involvement by MZL at other sites.…”
Section: Primary Cutaneous Marginal Zone Lymphomamentioning
confidence: 99%
“…Even more helpful is testing of samples from more than 1 site. Several studies [59][60][61] have demonstrated that detecting the same clone from different sites, including a single skin and peripheral blood sample, increases the reliability of these tests. Therefore, when results are questionable, one can request retesting on a new sample for comparison of the possible clone.…”
Section: Use Of Clonality Studies In the Diagnosismentioning
confidence: 99%